Brief: Clarity's U.S.-Based Cu-64 SAR-bisPSMA Trial In Prostate Cancer Opens For Recruitment
28/03/2022 14:53
March 28 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* CLARITY'S US-BASED CU-64 SAR-BISPSMA TRIAL IN PROSTATE
CANCER
OPENS FOR RECRUITMENT
Source text for Eikon: ID:nPnbpnL8ka
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial